These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 26682548)
1. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Mühlbacher A; Bethge S Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548 [TBL] [Abstract][Full Text] [Related]
2. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623 [TBL] [Abstract][Full Text] [Related]
3. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. Fifer S; Rose J; Hamrosi KK; Swain D BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844 [TBL] [Abstract][Full Text] [Related]
4. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment. Donnan JR; Johnston K; Chibrikov E; Marra CA; Aubrey-Bassler K; Najafzadeh M; Nguyen H; Gamble JM Can J Diabetes; 2020 Feb; 44(1):6-13. PubMed ID: 31311729 [TBL] [Abstract][Full Text] [Related]
5. Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. Mühlbacher AC; Sadler A; Juhnke C Eur J Health Econ; 2021 Apr; 22(3):425-443. PubMed ID: 33587221 [TBL] [Abstract][Full Text] [Related]
6. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594 [TBL] [Abstract][Full Text] [Related]
7. Reduce mortality risk above all else: a discrete-choice experiment in acute coronary syndrome patients. Mühlbacher AC; Bethge S Pharmacoeconomics; 2015 Jan; 33(1):71-81. PubMed ID: 25342231 [TBL] [Abstract][Full Text] [Related]
8. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey. Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681 [TBL] [Abstract][Full Text] [Related]
9. Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Janssen EM; Hauber AB; Bridges JFP Value Health; 2018 Jan; 21(1):59-68. PubMed ID: 29304942 [TBL] [Abstract][Full Text] [Related]
10. [Patients' preferences in the medicamentous treatment of diabetes mellitus type 2: A systematic classification and meta-comparison of patient preference studies]. Mühlbacher AC; Kaczynski A Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Apr; 58(4-5):452-66. PubMed ID: 25687713 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Chuang LH; Zhang H; Hong T; Xie S Patient; 2024 Sep; 17(5):565-574. PubMed ID: 38642244 [TBL] [Abstract][Full Text] [Related]
12. Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Petrak F; Herpertz S; Stridde E; Pfützner A Diabetes Technol Ther; 2013 Aug; 15(8):703-11. PubMed ID: 23844571 [TBL] [Abstract][Full Text] [Related]
13. Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences. von Arx LB; Johnson FR; Mørkbak MR; Kjær T Value Health; 2017 Apr; 20(4):670-678. PubMed ID: 28408010 [TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122 [TBL] [Abstract][Full Text] [Related]
15. A quantitative assessment of patient barriers to insulin. Casciano R; Malangone E; Ramachandran A; Gagliardino JJ Int J Clin Pract; 2011 Apr; 65(4):408-14. PubMed ID: 21401829 [TBL] [Abstract][Full Text] [Related]
16. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280 [No Abstract] [Full Text] [Related]
17. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies. Xie L; Wei W; Pan C; Baser O J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434 [TBL] [Abstract][Full Text] [Related]